Media stories about Biocept (NASDAQ:BIOC) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Biocept earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.9225252080655 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Liquid Biopsy Products Market to Witness Increase in Revenues by 2025 (sbwire.com)
- Mid-Afternoon Market Update: Vera Bradley Rises On Earnings Beat; Fred’s Shares Plunge (fxstreet.com)
- Mid-Day Market Update: Crude Oil Down 1.5%; AeroVironment Shares Climb After Strong Q2 Results (nasdaq.com)
- BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept (reuters.com)
- What Spooked Biocept Inc (BIOC) Investors Today (finance.yahoo.com)
Several brokerages have issued reports on BIOC. Chardan Capital reissued a “buy” rating and issued a $1.50 price target (down previously from $2.50) on shares of Biocept in a report on Tuesday, November 14th. Zacks Investment Research lowered shares of Biocept from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. Finally, ValuEngine downgraded shares of Biocept from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Biocept has a consensus rating of “Hold” and a consensus price target of $2.25.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/12/10/biocept-bioc-receiving-somewhat-favorable-media-coverage-study-shows.html.
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
What are top analysts saying about Biocept Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biocept Inc and related companies.